OBJECTIVES: To analyse the processes used in the adoption of new and emerging omic or genetic technologies in the Health Systems. METHODS: We have conducted literature searches and have direct contact with industries producing omic technologies of our networks of experts GENTECS and SORTEK for sharing information. Furthermore, we have checked various guidelines and strategies defined to regulate the introduction of such technologies in health systems established  by members of EuroScan or other agencies. RESULTS: Many omic technologies have been “on the horizon” and have shown promising results at the experimental level so are of interest to horizon scanners. But in many cases, those promising results haven’t then developed into real products to be applied in the health care sector. Many factors have contributed to this failure to cross the barrier, the paradigm in the system diagnosis-pathology, the lack of treatment or management options and the promising sector of individualized medicine or pharmacogenetics. Different actions and initiatives established by some HTA agencies in terms of developing guidelines and rationales that could help producers and systems in the adoption of these kinds of technologies have been studied and compared. We have found some guidelines and projects that could help in the adoption of omic technologies as the GEN guideline, the National Task Force on Genomics of the European Union, and some others, and we have identify some omic technologies for the diagnosis and prognosis of different genetically complex diseases. CONCLUSIONS: New and emerging omic technologies have opened new possibilities to more accurate diagnosis and treatments; moreover they have provided invaluable information that could guide preventative actions on health. However, we should consider the ethical and social consequences that could be caused by implementing preventative actions based on susceptibilities and not on certainties.